Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing PartnershipBusiness Wire • 10/18/22
Charles River Laboratories Schedules Third-Quarter 2022 Earnings Release and Conference CallBusiness Wire • 10/11/22
Charles River Launches nAAVigation Vector Platform to Accelerate Gene Therapy ProgramsBusiness Wire • 10/10/22
Dynamo Software Appoints New CTO From Charles River® to Lead FinTech Strategy, Engineering & IntegrationBusiness Wire • 09/28/22
Charles River Laboratories: A 'Picks And Shovels' Biomedical Play, Now Attractively PricedSeeking Alpha • 09/10/22
Charles River and Cure AP-4 Announce Gene Therapy Manufacturing CollaborationBusiness Wire • 09/06/22
Why Is Charles River (CRL) Down 10.7% Since Last Earnings Report?Zacks Investment Research • 09/02/22
Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogeneic Cell Therapy Drug ProductBusiness Wire • 08/09/22
Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/03/22
Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference CallBusiness Wire • 07/11/22
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based VaccineBusiness Wire • 06/23/22